#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Arrhythmogenic right ventricular dysplasia Paraganglion neoplasm Neuroendocrine carcinoma metastatic Type IIa hyperlipidaemia B-cell lymphoma refractory Philadelphia chromosome positive Extranodal marginal zone B-cell lymphoma (MALT type) Cutaneous T-cell lymphoma stage II Pleomorphic leiomyosarcoma Chronic granulomatous disease Autoimmune disorder Immunodeficiency common variable Indolent systemic mastocytosis Ductal adenocarcinoma of pancreas Lennox-Gastaut syndrome More trials…

    Learn about Rare Diseases

    Sarcoidosis Activated PI3 kinase delta syndrome Phenylketonuria Osteosarcoma – Basic Information Haemolytic uraemic syndrome – Treatment Pleural mesothelioma malignant – Trials in Disease VEXAS syndrome – Diagnostics Cerebral arteriovenous malformation haemorrhagic Familial amyotrophic lateral sclerosis – Treatment Glycogen storage disease type I – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tyrosine Dexamethasone Base Iph6501 Gefurulimab ALPROSTADIL Esflurbiprofen Edoxaban Soya Oil Temozolomide Olanzapine ALLO-QUADCAR01-T BUMETANIDE Tolinapant Lactate Isis 696844 XELAFASLATIDE Tofersen Meropenem Trihydrate S-241656 Idecabtagene Vicleucel Avacincaptad Pegol More therapies…

    Learn about Your Condition

    Retinal artery occlusion Oesophageal achalasia Tonsillitis Pleomorphic liposarcoma Metastasis Menopause Proteinuria Albuminuria Brain cancer metastatic Colorectal adenocarcinoma Skin angiosarcoma Transitional cell carcinoma Paraesthesia Penile cancer Tardive dyskinesia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Arteriosclerosis

  • Long-term Safety Study of INZ-701 for Patients with ENPP1 and ABCC6 Deficiencies, Including Pseudoxanthoma Elasticum and Generalized Arterial Calcification of Infancy

    Recruiting

    2 1 1
    Investigated Diseases:
    • Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency
    • Pseudoxanthoma elasticum
    • Arteriosclerosis
    Investigated Drugs:
    • Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
    France Germany

  • Study on the Best Antithrombotic Therapy for Patients with Acute Venous Thromboembolism Using Tinzaparin Sodium and Drug Combination

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Acenocoumarol
    • D,L-Lysine Acetylsalicylate
    • Dalteparin Sodium
    France

  • Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

    Recruiting

    4 1
    Investigated Drugs:
    • Clazakizumab
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

    Recruiting

    3 1 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Pelacarsen
    Austria Belgium Bulgaria Czechia Denmark France +14

  • Study of pelacarsen and inclisiran in patients with atherosclerotic cardiovascular disease who have high levels of LDL cholesterol and lipoprotein(a)

    Recruiting

    3 1 1
    Investigated Drugs:
    • Inclisiran
    • Pelacarsen
    France Germany Italy The Netherlands Spain

  • Study of Olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Austria Belgium Bulgaria Czechia Denmark France +11
Previous Page
1 2 3 4 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!